


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**ENTERING INTO EXCLUSIVE LICENSE AND COOPERATION AGREEMENT**  
**WITH INVENTISBIO**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**” or “**Sino Biopharmaceutical**”) announces that Chia-Tai Tianqing Pharmaceutical Group Co., Ltd. (“**Chia-Tai Tianqing**”), a subsidiary of the Company, entered into an exclusive license and cooperation agreement with Inventisbio Co. Ltd. (“**Inventisbio**”), pursuant to which Chia-Tai Tianqing was granted an exclusive license by Inventisbio to develop, register, manufacture and commercialize D-1553 in Mainland China. In addition, based on potential future cooperation in data sharing, Chia-Tai Tianqing will be granted a certain percentage of rights outside Mainland China in due course.

D-1553 is a KRAS G12C inhibitor independently developed by Inventisbio, used for the treatment of non-small cell lung cancer (“**NSCLC**”), colorectal cancer and other cancers carrying KRAS G12C mutation. It is the first KRAS G12C inhibitor that is independently developed and has entered the clinical trial stage in Mainland China, and international multi-center clinical trials of D-1553 have been carried out in the United States, Australia, China, South Korea, Taiwan, China and other countries and regions. In May 2022, D-1553 received approval from the Center for Drug Evaluation of the National Medical Products Administration of China to conduct a phase II clinical trial as monotherapy for the treatment of KRAS G12C mutation-positive NSCLC. Currently, D-1553 is undergoing international multi-center clinical studies for monotherapy and combination therapy in the first-line treatment of NSCLC as well as other solid tumors such as colorectal cancer, and is in the phase II clinical trial stage.

Oncology is one of the four major therapeutic areas of Sino Biopharmaceutical's innovation and development. After years of intensive cultivation, a number of heavyweight products have been launched, and several innovative drug projects are in the clinical development stage. The introduction of D-1553 will further enrich Sino Biopharmaceutical's oncology innovative drug pipeline and improve Sino Biopharmaceutical's strategic layout in the oncology field. With its extensive experience in innovative research and development, drug manufacturing and commercialisation, Sino Biopharmaceutical will accelerate the launch of this product to meet the urgent needs of oncology patients.

### **About Investisobio**

As a China-based innovative drug discovery and development company with a global perspective, Investisobio is listed on the Shanghai Stock Exchange STAR Market (Stock Code: 688382). Focusing on major diseases such as oncology and metabolic diseases, Investisobio is committed to developing innovative drugs with independent intellectual property rights, which are created in China and available globally with the philosophy of solving unmet clinical needs and providing patients with safer, more effective and more affordable therapeutic solutions in a persistent manner. Leveraging its in-depth research and understanding of disease mechanisms, Investisobio selects potential drug targets and designs drugs based on the binding conformation of the compounds with the targets to ensure excellent human safety while realising precise treatment of diseases. Based on its outstanding and extensive drug development strength and experience, Investisobio has developed a series of innovative targeted drugs with patent protection, covering NSCLC, breast cancer, colorectal cancer and other solid tumors, as well as autoimmune diseases and metabolic diseases.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 3 August 2023

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*